Product
Crinecerfont
Aliases
NBI-74788
2 clinical trials
1 indication
Indication
Congenital Adrenal HyperplasiaClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-07-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label TreatmentStatus: Active (not recruiting), Estimated PCD: 2023-03-10